Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cold-adapted influenza vaccine trivalent (CAIV-T)
Cold-adapted influenza vaccine trivalent · 2 trials · 1 indication
The criteria for obtaining nasal and throat swabs for viral culture were any one of the following: A feeling of "feverishness", An oral temperature ≥37.2ºC, Sore throat, New or increased cough, Malaise, Myalgia. Swabs for viral cultures were also obtained, if, in the opinion of the investigator, the symptom complex so warranted.
| Arm | Type | Description |
|---|---|---|
| Cold-adapted influenza vaccine trivalent (CAIV-T) | EXPERIMENTAL | A single 0.2 mL dose of 10\^7 fluorescent focus units was administered intranasally. |
| Trivalent Inactivated Vaccine (TIV) | ACTIVE_COMPARATOR | A single dose was administered by intramuscular injection. |
| CAIV-T | EXPERIMENTAL | The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril). |
| Placebo | PLACEBO_COMPARATOR | The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril). |
| Name | Type | Description |
|---|---|---|
| Cold-adapted influenza vaccine trivalent (CAIV-T) | BIOLOGICAL | Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5. |
| Trivalent Inactivated Vaccine (TIV) | BIOLOGICAL | Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults). |
| Placebo | BIOLOGICAL | The placebo consisted of physiologic normal saline. |
Inclusion Criteria: * who are aged at least 60 years or older at the time of enrollment; * who are determined by medical history, physical examination and clinical judgement to be eligible for this study; * who have provided written informed consent after the nature of the study has been explained;...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
Cold-adapted influenza vaccine trivalent is a vaccine being developed for the prevention of influenza. It is designed to protect against influenza virus types A and B. The vaccine has been studied in adults aged 60 years and older and in healthy children and adolescents aged 6 to less than 18 years.
Cold-adapted influenza vaccine trivalent is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the company responsible for the clinical development of this influenza vaccine candidate.
Cold-adapted influenza vaccine trivalent is in Phase 3 clinical development. A Phase 3 trial has been completed, and a Phase 2 trial has also been completed. The vaccine remains an investigational product and has not been approved by the FDA.
Cold-adapted influenza vaccine trivalent has been evaluated in two completed clinical trials. NCT00192413 was a Phase 3 trial in adults aged 60 years and older in South Africa, enrolling 3,009 participants. NCT00192179 was a Phase 2 trial in healthy children and adolescents aged 6 to less than 18 years in Belgium, Poland, and the United Kingdom, enrolling 240 participants.
Yes, cold-adapted influenza vaccine trivalent is also known as CAIV-T. CAIV-T is the abbreviated name for this influenza vaccine candidate. Both names refer to the same investigational vaccine developed by AstraZeneca PLC for the prevention of influenza.